26 results on '"Hartnett, Jessica N."'
Search Results
2. Analysis of CD8⁺ T cell response during the 2013–2016 Ebola epidemic in West Africa
- Author
-
Sakabe, Saori, Sullivan, Brian M., Hartnett, Jessica N., Robles-Sikisaka, Refugio, Gangavarapu, Karthik, Cubitt, Beatrice, Ware, Brian C., Kotliar, Dylan, Branco, Luis M., Goba, Augustine, Momoh, Mambu, Sandi, John Demby, Kanneh, Lansana, Grant, Donald S., Garry, Robert F., Andersen, Kristian G., de la Torre, Juan Carlos, Sabeti, Pardis C., Schieffelin, John S., and Oldstone, Michael B. A.
- Published
- 2018
3. Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) Study: Reverse Transcription-Polymerase Chain Reaction and Cataract Surgery Outcomes of Ebola Survivors in Sierra Leone
- Author
-
Shantha, Jessica G., Mattia, John G., Goba, Augustine, Barnes, Kayla G., Ebrahim, Faiqa K., Kraft, Colleen S., Hayek, Brent R., Hartnett, Jessica N., Shaffer, Jeffrey G., Schieffelin, John S., Sandi, John D., Momoh, Mambu, Jalloh, Simbirie, Grant, Donald S., Dierberg, Kerry, Chang, Joyce, Mishra, Sharmistha, Chan, Adrienne K., Fowler, Rob, O'Dempsey, Tim, Kaluma, Erick, Hendricks, Taylor, Reiners, Roger, Reiners, Melanie, Gess, Lowell A., ONeill, Kwame, Kamara, Sarian, Wurie, Alie, Mansaray, Mohamed, Acharya, Nisha R., Liu, William J., Bavari, Sina, Palacios, Gustavo, Teshome, Moges, Crozier, Ian, Farmer, Paul E., Uyeki, Timothy M., Bausch, Daniel G., Garry, Robert F., Vandy, Matthew J., and Yeh, Steven
- Published
- 2018
- Full Text
- View/download PDF
4. An Outbreak of Ebola Virus Disease in the Lassa Fever Zone
- Author
-
Goba, Augustine, Khan, S. Humarr, Fonnie, Mbalu, Fullah, Mohamed, Moigboi, Alex, Kovoma, Alice, Sinnah, Vandi, Yoko, Nancy, Rogers, Hawa, Safai, Siddiki, Momoh, Mambu, Koroma, Veronica, Kamara, Fatima K., Konowu, Edwin, Yillah, Mohamed, French, Issa, Mustapha, Ibraham, Kanneh, Franklyn, Foday, Momoh, McCarthy, Helena, Kallon, Tiangay, Kallon, Mustupha, Naiebu, Jenneh, Sellu, Josephine, Jalloh, Abdul A., Gbakie, Michael, Kanneh, Lansana, Massaly, James L. B., Kargbo, David, Kargbo, Brima, Vandi, Mohamed, Gbetuwa, Momoh, Gevao, Sahr M., Sandi, John D., Jalloh, Simbirie C., Grant, Donald S., Blyden, Sylvia O., Crozier, Ian, Schieffelin, John S., McLellan, Susan L., Jacob, Shevin T., Boisen, Matt L., Hartnett, Jessica N., Cross, Robert W., Branco, Luis M., Andersen, Kristian G., Yozwiak, Nathan L., Gire, Stephen K., Tariyal, Ridhi, Park, Daniel J., Haislip, Allyson M., Bishop, Christopher M., Melnik, Lilia I., Gallaher, William R., Wimley, William C., He, Jing, Shaffer, Jeffrey G., Sullivan, Brian M., Grillo, Sonia, Oman, Scott, Garry, Courtney E., Edwards, Donna R., McCormick, Stephanie J., Elliott, Deborah H., Rouelle, Julie A., Kannadka, Chandrika B., Reyna, Ashley A., Bradley, Benjamin T., Yu, Haini, Yenni, Rachael E., Hastie, Kathryn M., Geisbert, Joan B., Kulakosky, Peter C., Wilson, Russell B., Oldstone, Michael B. A., Pitts, Kelly R., Henderson, Lee A., Robinson, James E., Geisbert, Thomas W., Saphire, Erica Ollmann, Happi, Christian T., Asogun, Danny A., Sabeti, Pardis C., and Garry, Robert F.
- Published
- 2016
5. Field Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection
- Author
-
Boisen, Matthew L., Cross, Robert W., Hartnett, Jessica N., Goba, Augustine, Momoh, Mambu, Fullah, Mohamed, Gbakie, Michael, Safa, Sidiki, Fonnie, Mbalu, Baimba, Francis, Koroma, Veronica J., Geisbert, Joan B., McCormick, Stephanie, Nelson, Diana K. S., Millett, Molly M., Oottamasathien, Darin, Jones, Abby B., Pham, Ha, Brown, Bethany L., Shaffer, Jeffrey G., Schieffelin, John S., Kargbo, Brima, Gbetuwa, Momoh, Gevao, Sahr M., Wilson, Russell B., Pitts, Kelly R., Geisbert, Thomas W., Branco, Luis M., Khan, Sheik H., Grant, Donald S., and Garry, Robert F.
- Published
- 2016
6. Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection
- Author
-
Cross, Robert W., Boisen, Matthew L., Millett, Molly M., Nelson, Diana S., Oottamasathien, Darin, Hartnett, Jessica N., Jones, Abigal B., Goba, Augustine, Momoh, Mambu, Fullah, Mohamed, Bornholdt, Zachary A., Fusco, Marnie L., Abelson, Dafna M., Oda, Shunichiro, Brown, Bethany L., Pham, Ha, Rowland, Megan M., Agans, Krystle N., Geisbert, Joan B., Heinrich, Megan L., Kulakosky, Peter C., Shaffer, Jeffrey G., Schieffelin, John S., Kargbo, Brima, Gbetuwa, Momoh, Gevao, Sahr M., Wilson, Russell B., Saphire, Erica Ollmann, Pitts, Kelly R., Khan, Sheik Humarr, Grant, Donald S., Geisbert, Thomas W., Branco, Luis M., and Garry, Robert F.
- Published
- 2016
7. Development of Prototype Filovirus Recombinant Antigen Immunoassays
- Author
-
Boisen, Matt L., Oottamasathien, Darin, Jones, Abigail B., Mille, Molly M., Nelson, Diana S., Bornholdt, Zachary A., Fusco, Marnie L., Abelson, Dafna M., Oda, Shun-ichiro, Hartnett, Jessica N., Rowland, Megan M., Heinrich, Megan L., Akdag, Marjan, Goba, Augustine, Momoh, Mambu, Fullah, Mohammed, Baimba, Francis, Gbakie, Michael, Safa, Sadiki, Fonnie, Richard, Kanneh, Lansana, Cross, Robert W., Geisbert, Joan B., Geisbert, Thomas W., Kulakosky, Peter C., Grant, Donald S., Shaffer, Jeffery G., Schieffelin, John S., Wilson, Russell B., Saphire, Erica Ollmann, Branco, Luis M., Garry, Robert F., Khan, S. Humarr, and Pitts, Kelly R.
- Published
- 2015
8. Zika Virus Non-Structural Protein 1 Antigen-Capture Immunoassay
- Author
-
Beddingfield, Brandon J., primary, Hartnett, Jessica N., additional, Wilson, Russell B., additional, Kulakosky, Peter C., additional, Andersen, Kristian G., additional, Robles-Sikisaka, Refugio, additional, Grubaugh, Nathan D., additional, Aybar, Argelia, additional, Nunez, Maria-Zunilla, additional, Fermin, Cesar D., additional, and Garry, Robert F., additional
- Published
- 2021
- Full Text
- View/download PDF
9. Posterior Segment Ophthalmic Manifestations in Ebola Survivors, Sierra Leone
- Author
-
Berry, Duncan E., primary, Bavinger, J. Clay, additional, Fernandes, Alcides, additional, Mattia, John G., additional, Mustapha, Jalikatu, additional, Harrison-Williams, Lloyd, additional, Teshome, Moges, additional, Vandy, Matthew J., additional, Shantha, Jessica G., additional, Yeh, Steven, additional, Hayek, Brent, additional, Kraft, Colleen S., additional, Crozier, Ian, additional, O’Neill, Kwame, additional, Kamara, Sarian, additional, Wurie, Alie, additional, Goba, Augustine, additional, Sandi, John D., additional, Momoh, Mambu, additional, Jalloh, Simbirie, additional, Grant, Donald S., additional, Farmer, Paul E., additional, Dierberg, Kerry, additional, Chang, Joyce, additional, Bausch, Daniel G., additional, Garry, Robert F., additional, Hartnett, Jessica N., additional, Shaffer, Jeffrey G., additional, Schieffelin, John S., additional, Acharya, Nisha R., additional, Uyeki, Timothy M., additional, Reiners, Roger, additional, Reiners, Melanie, additional, Gess, Lowell A., additional, Mansaray, Mohamed, additional, Kabba, Yusuf, additional, Kamara, Daddy, additional, Mishra, Sharmistha, additional, Chan, Adrienne K., additional, Fowler, Rob, additional, O’Dempsey, Tim, additional, Liu, William J., additional, Ebrahim, Faiqa K., additional, Hendricks, Taylor, additional, Kaluma, Erick, additional, Bavari, Sina, additional, and Palacios, Gustavo, additional
- Published
- 2021
- Full Text
- View/download PDF
10. Identification of Common CD8 + T Cell Epitopes from Lassa Fever Survivors in Nigeria and Sierra Leone
- Author
-
Sakabe, Saori, primary, Hartnett, Jessica N., additional, Ngo, Nhi, additional, Goba, Augustine, additional, Momoh, Mambu, additional, Sandi, John Demby, additional, Kanneh, Lansana, additional, Cubitt, Beatrice, additional, Garcia, Selma D., additional, Ware, Brian C., additional, Kotliar, Dylan, additional, Robles-Sikisaka, Refugio, additional, Gangavarapu, Karthik, additional, Branco, Luis M., additional, Eromon, Philomena, additional, Odia, Ikponmwosa, additional, Ogbaini-Emovon, Ephraim, additional, Folarin, Onikepe, additional, Okogbenin, Sylvanus, additional, Okokhere, Peter O., additional, Happi, Christian, additional, Sabeti, Pardis C., additional, Andersen, Kristian G., additional, Garry, Robert F., additional, de la Torre, Juan Carlos, additional, Grant, Donald S., additional, Schieffelin, John S., additional, Oldstone, Michael B. A., additional, and Sullivan, Brian M., additional
- Published
- 2020
- Full Text
- View/download PDF
11. Reevaluating HLA-A2-restricted Lassa epitopes in human Lassa fever survivors
- Author
-
Sullivan, Brian Martin, primary, Sakabe, Saori, additional, Hartnett, Jessica N, additional, Nho, Nhi, additional, Goba, Augustine, additional, Momoh, Mambu, additional, Sandi, John Demby, additional, Kanneh, Lansana, additional, Cubitt, Beatrice, additional, Garcia, Selma D, additional, Ware, Brian C, additional, Kotliar, Dylan, additional, Robles-Sikisaka, Refugio, additional, Gangavarapu, Karthik, additional, de la Torre, Juan Carlos, additional, Sabeti, Pardis C, additional, Andersen, Kristian G, additional, Garry, Robert F, additional, Grant, Donald S, additional, Schieffelin, John S, additional, and Oldstone, Michael B, additional
- Published
- 2020
- Full Text
- View/download PDF
12. High crossreactivity of human T cell responses between Lassa virus lineages
- Author
-
Sullivan, Brian M., primary, Sakabe, Saori, additional, Hartnett, Jessica N., additional, Ngo, Nhi, additional, Goba, Augustine, additional, Momoh, Mambu, additional, Demby Sandi, John, additional, Kanneh, Lansana, additional, Cubitt, Beatrice, additional, Garcia, Selma D., additional, Ware, Brian C., additional, Kotliar, Dylan, additional, Robles-Sikisaka, Refugio, additional, Gangavarapu, Karthik, additional, Branco, Luis, additional, Eromon, Philomena, additional, Odia, Ikponmwosa, additional, Ogbaini-Emovon, Ephraim, additional, Folarin, Onikepe, additional, Okogbenin, Sylvanus, additional, Okokhere, Peter O., additional, Happi, Christian, additional, de la Torre, Juan Carlos, additional, Sabeti, Pardis C., additional, Andersen, Kristian G., additional, Garry, Robert F., additional, Grant, Donald S., additional, Schieffelin, John S., additional, and Oldstone, Michael B. A., additional
- Published
- 2020
- Full Text
- View/download PDF
13. Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses
- Author
-
Gunn, Bronwyn M, primary, Roy, Vicky, primary, Karim, Marcus M, primary, Hartnett, Jessica N, primary, Suscovich, Todd J, primary, Goba, Augustine, primary, Momoh, Mambu, primary, Sandi, John Demby, primary, Kanneh, Lansana, primary, Andersen, Kristian G, primary, Shaffer, Jeffrey G, primary, Schieffelin, John S, primary, Garry, Robert F, primary, Grant, Donald S, primary, and Alter, Galit, primary
- Published
- 2019
- Full Text
- View/download PDF
14. Data set on Lassa fever in post-conflict Sierra Leone
- Author
-
Shaffer, Jeffrey G., primary, Schieffelin, John S., additional, Grant, Donald S., additional, Goba, Augustine, additional, Momoh, Mambu, additional, Kanneh, Lansana, additional, Levy, Danielle C., additional, Hartnett, Jessica N., additional, Boisen, Matt L., additional, Branco, Luis M., additional, and Garry, Robert F., additional
- Published
- 2019
- Full Text
- View/download PDF
15. Identification of Common CD8+ T Cell Epitopes from Lassa Fever Survivors in Nigeria and Sierra Leone.
- Author
-
Sakabe, Saori, Hartnett, Jessica N., Nhi Ngo, Goba, Augustine, Momoh, Mambu, Sandi, John Demby, Kanneh, Lansana, Cubitt, Beatrice, Garcia, Selma D., Ware, Brian C., Kotliar, Dylan, Robles-Sikisaka, Refugio, Gangavarapu, Karthik, Branco, Luis M., Eromon, Philomena, Odia, Ikponmwosa, Ogbaini-Emovon, Ephraim, Folarin, Onikepe, Okogbenin, Sylvanus, and Okokhere, Peter O.
- Subjects
- *
T cells , *LASSA fever , *EPITOPES , *CELLULAR immunity , *HAPLOTYPES - Abstract
Early and robust T cell responses have been associated with survival from Lassa fever (LF), but the Lassa virus-specific memory responses have not been well characterized. Regions within the virus surface glycoprotein (GPC) and nucleoprotein (NP) are the main targets of the Lassa virus-specific T cell responses, but, to date, only a few T cell epitopes within these proteins have been identified. We identified GPC and NP regions containing T cell epitopes and HLA haplotypes from LF survivors and used predictive HLA-binding algorithms to identify putative epitopes, which were then experimentally tested using autologous survivor samples. We identified 12 CD8-positive (CD8+) T cell epitopes, including epitopes common to both Nigerian and Sierra Leonean survivors. These data should be useful for the identification of dominant Lassa virus-specific T cell responses in Lassa fever survivors and vaccinated individuals as well as for designing vaccines that elicit cell-mediated immunity. IMPORTANCE The high morbidity and mortality associated with clinical cases of Lassa fever, together with the lack of licensed vaccines and limited and partially effective interventions, make Lassa virus (LASV) an important health concern in its regions of endemicity in West Africa. Previous infection with LASV protects from disease after subsequent exposure, providing a framework for designing vaccines to elicit similar protective immunity. Multiple major lineages of LASV circulate in West Africa, and therefore, ideal vaccine candidates should elicit immunity to all lineages. We therefore sought to identify common T cell epitopes between Lassa fever survivors from Sierra Leone and Nigeria, where distinct lineages circulate. We identified three such epitopes derived from highly conserved regions within LASV proteins. In this process, we also identified nine other T cell epitopes. These data should help in the design of an effective pan-LASV vaccine. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses.
- Author
-
Gunn, Bronwyn M, Roy, Vicky, Karim, Marcus M, Hartnett, Jessica N, Suscovich, Todd J, Goba, Augustine, Momoh, Mambu, Sandi, John Demby, Kanneh, Lansana, Andersen, Kristian G, Shaffer, Jeffrey G, Schieffelin, John S, Garry, Robert F, Grant, Donald S, Alter, Galit, and Goba, Augustin
- Subjects
EBOLA virus disease ,ANTIBODY formation ,EBOLA virus ,MONOCLONAL antibodies ,ACUTE diseases ,VIRAL antigens ,IMMUNOGLOBULINS ,PHAGOCYTOSIS ,IMMUNITY ,RESEARCH funding ,VIRAL antibodies - Abstract
Monoclonal antibodies can mediate protection against Ebola virus (EBOV) infection through direct neutralization as well as through the recruitment of innate immune effector functions. However, the antibody functional response following survival of acute EBOV disease has not been well characterized. In this study, serum antibodies from Ebola virus disease (EVD) survivors from Sierra Leone were profiled to capture variation in overall subclass/isotype abundance, neutralizing activity, and innate immune effector functions. Antibodies from EVD survivors exhibited robust innate immune effector functions, mediated primarily by IgG1 and IgA1. In conclusion, development of functional antibodies follows survival of acute EVD. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Analysis of CD8 + T cell response during the 2013–2016 Ebola epidemic in West Africa
- Author
-
Sakabe, Saori, primary, Sullivan, Brian M., additional, Hartnett, Jessica N., additional, Robles-Sikisaka, Refugio, additional, Gangavarapu, Karthik, additional, Cubitt, Beatrice, additional, Ware, Brian C., additional, Kotliar, Dylan, additional, Branco, Luis M., additional, Goba, Augustine, additional, Momoh, Mambu, additional, Sandi, John Demby, additional, Kanneh, Lansana, additional, Grant, Donald S., additional, Garry, Robert F., additional, Andersen, Kristian G., additional, de la Torre, Juan Carlos, additional, Sabeti, Pardis C., additional, Schieffelin, John S., additional, and Oldstone, Michael B. A., additional
- Published
- 2018
- Full Text
- View/download PDF
18. Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever
- Author
-
Boisen, Matthew L., primary, Hartnett, Jessica N., additional, Shaffer, Jeffrey G., additional, Goba, Augustine, additional, Momoh, Mambu, additional, Sandi, John Demby, additional, Fullah, Mohamed, additional, Nelson, Diana K. S., additional, Bush, Duane J., additional, Rowland, Megan M., additional, Heinrich, Megan L., additional, Koval, Anatoliy P., additional, Cross, Robert W., additional, Barnes, Kayla G., additional, Lachenauer, Anna E., additional, Lin, Aaron E., additional, Nekoui, Mahan, additional, Kotliar, Dylan, additional, Winnicki, Sarah M., additional, Siddle, Katherine J., additional, Gbakie, Michael, additional, Fonnie, Mbalu, additional, Koroma, Veronica J., additional, Kanneh, Lansana, additional, Kulakosky, Peter C., additional, Hastie, Kathryn M., additional, Wilson, Russell B., additional, Andersen, Kristian G., additional, Folarin, Onikepe O., additional, Happi, Christian T., additional, Sabeti, Pardis C., additional, Geisbert, Thomas W., additional, Saphire, Erica Ollmann, additional, Khan, S. Humarr, additional, Grant, Donald S., additional, Schieffelin, John S., additional, Branco, Luis M., additional, and Garry, Robert F., additional
- Published
- 2018
- Full Text
- View/download PDF
19. A medical records and data capture and management system for Lassa fever in Sierra Leone: Approach, implementation, and challenges.
- Author
-
Shaffer, Jeffrey G., Schieffelin, John S., Gbakie, Michael, Alhasan, Foday, Roberts, Nicole B., Goba, Augustine, Randazzo, Jessica, Momoh, Mambu, Moon, Troy D., Kanneh, Lansana, Levy, Danielle C., Podgorski, Rachel M., Hartnett, Jessica N., Boisen, Matt L., Branco, Luis M., Samuels, Robert, Grant, Donald S., Garry, Robert F., and null, null
- Subjects
HEMORRHAGIC fever ,EBOLA virus disease ,COMPUTER equipment ,ENZYME-linked immunosorbent assay ,MEDICAL records ,FEVER - Abstract
Situated in southeastern Sierra Leone, Kenema Government Hospital (KGH) maintains one of the world’s only Lassa fever isolation wards and was a strategic Ebola virus disease (EVD) treatment facility during the 2014 EVD outbreak. Since 2006, the Viral Hemorrhagic Fever Consortium (VHFC) has carried out research activities at KGH, capturing clinical and laboratory data for suspected cases of Lassa fever. Here we describe the approach, progress, and challenges in designing and maintaining a data capture and management system (DCMS) at KGH to assist infectious disease researchers in building and sustaining DCMS in low-resource environments. Results on screening patterns and case-fatality rates are provided to illustrate the context and scope of the DCMS covered in this study. A medical records system and DCMS was designed and implemented between 2010 and 2016 linking historical and prospective Lassa fever data sources across KGH Lassa fever units and its peripheral health units. Data were captured using a case report form (CRF) system, enzyme-linked immunosorbent assay (ELISA) plate readers, polymerase chain reaction (PCR) machines, blood chemistry analyzers, and data auditing procedures. Between 2008 and 2016, blood samples for 4,229 suspected Lassa fever cases were screened at KGH, ranging from 219 samples in 2008 to a peak of 760 samples in 2011. Lassa fever case-fatality rates before and following the Ebola outbreak were 65.5% (148/226) and 89.5% (17/19), respectively, suggesting that fewer, but more seriously ill subjects with Lassa fever presented to KGH following the 2014 EVD outbreak (p = .040). DCMS challenges included weak specificity of the Lassa fever suspected case definition, limited capture of patient survival outcome data, internet costs, lapses in internet connectivity, low bandwidth, equipment and software maintenance, lack of computer teaching laboratories, and workload fluctuations due to variable screening activity. DCMS are the backbone of international research efforts and additional literature is needed on the topic for establishing benchmarks and driving goal-based approaches for its advancement in developing countries. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits
- Author
-
Robinson, James E., primary, Hastie, Kathryn M., additional, Cross, Robert W., additional, Yenni, Rachael E., additional, Elliott, Deborah H., additional, Rouelle, Julie A., additional, Kannadka, Chandrika B., additional, Smira, Ashley A., additional, Garry, Courtney E., additional, Bradley, Benjamin T., additional, Yu, Haini, additional, Shaffer, Jeffrey G., additional, Boisen, Matt L., additional, Hartnett, Jessica N., additional, Zandonatti, Michelle A., additional, Rowland, Megan M., additional, Heinrich, Megan L., additional, Martínez-Sobrido, Luis, additional, Cheng, Benson, additional, de la Torre, Juan C., additional, Andersen, Kristian G., additional, Goba, Augustine, additional, Momoh, Mambu, additional, Fullah, Mohamed, additional, Gbakie, Michael, additional, Kanneh, Lansana, additional, Koroma, Veronica J., additional, Fonnie, Richard, additional, Jalloh, Simbirie C., additional, Kargbo, Brima, additional, Vandi, Mohamed A., additional, Gbetuwa, Momoh, additional, Ikponmwosa, Odia, additional, Asogun, Danny A., additional, Okokhere, Peter O., additional, Follarin, Onikepe A., additional, Schieffelin, John S., additional, Pitts, Kelly R., additional, Geisbert, Joan B., additional, Kulakoski, Peter C., additional, Wilson, Russell B., additional, Happi, Christian T., additional, Sabeti, Pardis C., additional, Gevao, Sahr M., additional, Khan, S. Humarr, additional, Grant, Donald S., additional, Geisbert, Thomas W., additional, Saphire, Erica Ollmann, additional, Branco, Luis M., additional, and Garry, Robert F., additional
- Published
- 2016
- Full Text
- View/download PDF
21. Analysis of CD8+ T cell response during the 2013-2016 Ebola epidemic in West Africa.
- Author
-
Saori Sakabe, Sullivan, Brian M., Hartnett, Jessica N., Robles-Sikisaka, Refugio, Gangavarapu, Karthik, Cubitt, Beatrice, Ware, Brian C., Kotliar, Dylan, Branco, Luis M., Goba, Augustine, Momoh, Mambu, Sandi, John Demby, Kanneh, Lansana, Grant, Donald S., Garry, Robert F., Andersen, Kristian G., de la Torre, Juan Carlos, Sabeti, Pardis C., Schieffelin, John S., and Oldstone, Michael B. A.
- Subjects
EBOLA virus ,EPIDEMICS ,IMMUNIZATION ,T cells ,PATHOGENIC microorganisms - Abstract
The recent Ebola epidemic exemplified the importance of understanding and controlling emerging infections. Despite the importance of T cells in clearing virus during acute infection, little is known about Ebola-specific CD8
+ T cell responses. We investigated immune responses of individuals infected with Ebola virus (EBOV) during the 2013-2016 West Africa epidemic in Sierra Leone, where the majority of the >28,000 EBOV disease (EVD) cases occurred. We examined T cell memory responses to seven of the eight Ebola proteins (GP, sGP, NP, VP24, VP30, VP35, and VP40) and associated HLA expression in survivors. Of the 30 subjects included in our analysis, CD8+ T cells from 26 survivors responded to at least one EBOV antigen. A minority, 10 of 26 responders (38%), made CD8+ T cell responses to the viral GP or sGP. In contrast, 25 of the 26 responders (96%) made response to viral NP, 77% to VP24 (20 of 26), 69% to VP40 (18 of 26), 42% (11 of 26) to VP35, with no response to VP30. Individuals making CD8+ T cells to EBOV VP24, VP35, and VP40 also made CD8+ T cells to NP, but rarely to GP. We identified 34 CD8+ T cell epitopes for Ebola. Our data indicate the immunodominance of the EBOV NP-specific T cell response and suggest that its inclusion in a vaccine along with the EBOV GP would best mimic survivor responses and help boost cell-mediated immunity during vaccination. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
22. Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever
- Author
-
Boisen, Matthew L., Hartnett, Jessica N., Shaffer, Jeffrey G., Goba, Augustine, Momoh, Mambu, Sandi, John Demby, Fullah, Mohamed, Nelson, Diana K. S., Bush, Duane J., Rowland, Megan M., Heinrich, Megan L., Koval, Anatoliy P., Cross, Robert W., Barnes, Kayla G., Lachenauer, Anna E., Lin, Aaron E., Nekoui, Mahan, Kotliar, Dylan, Winnicki, Sarah M., Siddle, Katherine J., Gbakie, Michael, Fonnie, Mbalu, Koroma, Veronica J., Kanneh, Lansana, Kulakosky, Peter C., Hastie, Kathryn M., Wilson, Russell B., Andersen, Kristian G., Folarin, Onikepe O., Happi, Christian T., Sabeti, Pardis C., Geisbert, Thomas W., Saphire, Erica Ollmann, Khan, S. Humarr, Grant, Donald S., Schieffelin, John S., Branco, Luis M., and Garry, Robert F.
- Abstract
Lassa fever, a hemorrhagic fever caused by Lassa virus (LASV), is endemic in West Africa. It is difficult to distinguish febrile illnesses that are common in West Africa from Lassa fever based solely on a patient’s clinical presentation. The field performance of recombinant antigen-based Lassa fever immunoassays was compared to that of quantitative polymerase chain assays (qPCRs) using samples from subjects meeting the case definition of Lassa fever presenting to Kenema Government Hospital in Sierra Leone. The recombinant Lassa virus (ReLASV) enzyme-linked immunosorbant assay (ELISA) for detection of viral antigen in blood performed with 95% sensitivity and 97% specificity using a diagnostic standard that combined results of the immunoassays and qPCR. The ReLASV rapid diagnostic test (RDT), a lateral flow immunoassay based on paired monoclonal antibodies to the Josiah strain of LASV (lineage IV), performed with 90% sensitivity and 100% specificity. ReLASV immunoassays performed better than the most robust qPCR currently available, which had 82% sensitivity and 95% specificity. The performance characteristics of recombinant antigen-based Lassa virus immunoassays indicate that they can aid in the diagnosis of LASV Infection and inform the clinical management of Lassa fever patients.
- Published
- 2018
- Full Text
- View/download PDF
23. Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever.
- Author
-
Hartnett, Jessica N, Boisen, Matthew L, Oottamasathien, Darin, Jones, Abigail B, Millett, Molly M, Nelson, Diana S, Muncy, Ivana J, Goba, Augustine, Momoh, Mambu, Fullah, Mohammed, Mire, Chad E, Geisbert, Joan B, Geisbert, Thomas W, Holton, Debra L, Rouelle, Julie A, Kannadka, Chandrika B, Reyna, Ashley A, Moses, Lina M, Khan, Sheik Humarr, and Gevao, Sahr M
- Abstract
Lassa fever (LF) is a potentially fatal disease that affects an estimated 300,000-500,000 people in endemic areas of west Africa each year. Though past studies have identified fatality rates of 5-20% in patients suspected to have contracted Lassa virus (LASV), new studies using more precise clinical diagnoses and modern diagnostic assays show fatalities rates above 60% in acutely ill patients from endemic regions. Currently, there are no approved vaccines or therapeutics, and only one Comformité Européenne (CE) marked rapid immunodiagnostic for acute LASV infection. Therefore, preventing LASV transmission is the primary goal in endemic regions. Development of rapid immunodiagnostics and research into the efficacy of current treatment options continues toward saving lives in west Africa as well as creating a line of defense against the nefarious use of LASV in bioterrorism settings. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
24. Multiple Circulating Infections Can Mimic the Early Stages of Viral Hemorrhagic Fevers and Possible Human Exposure to Filoviruses in Sierra Leone Prior to the 2014 Outbreak.
- Author
-
Boisen, Matthew L., Schieffelin, John S., Goba, Augustine, Oottamasathien, Darin, Jones, Abigail B., Shaffer, Jeffrey G., Hastie, Kathryn M., Hartnett, Jessica N., Momoh, Mambu, Fullah, Mohammed, Gabiki, Michael, Safa, Sidiki, Zandonatti, Michelle, Fusco, Marnie, Bornholdt, Zach, Abelson, Dafna, Gire, Stephen K., Andersen, Kristian G., Tariyal, Ridhi, and Stremlau, Mathew
- Published
- 2015
- Full Text
- View/download PDF
25. Lassa Fever in Post-Conflict Sierra Leone.
- Author
-
Shaffer, Jeffrey G., Grant, Donald S., Schieffelin, John S., Boisen, Matt L., Goba, Augustine, Hartnett, Jessica N., Levy, Danielle C., Yenni, Rachael E., Moses, Lina M., Fullah, Mohammed, Momoh, Mambo, Fonnie, Mbalu, Fonnie, Richard, Kanneh, Lansana, Koroma, Veronica J., Kargbo, Kandeh, Ottomassathien, Darin, Muncy, Ivana J., Jones, Abigail B., and Illick, Megan M.
- Subjects
LASSA fever ,HEMORRHAGIC diseases ,YOUNG adults ,DEATH rate ,PUBLIC hospitals - Abstract
Background: Lassa fever (LF), an often-fatal hemorrhagic disease caused by Lassa virus (LASV), is a major public health threat in West Africa. When the violent civil conflict in Sierra Leone (1991 to 2002) ended, an international consortium assisted in restoration of the LF program at Kenema Government Hospital (KGH) in an area with the world's highest incidence of the disease. Methodology/Principal Findings: Clinical and laboratory records of patients presenting to the KGH Lassa Ward in the post-conflict period were organized electronically. Recombinant antigen-based LF immunoassays were used to assess LASV antigenemia and LASV-specific antibodies in patients who met criteria for suspected LF. KGH has been reestablished as a center for LF treatment and research, with over 500 suspected cases now presenting yearly. Higher case fatality rates (CFRs) in LF patients were observed compared to studies conducted prior to the civil conflict. Different criteria for defining LF stages and differences in sensitivity of assays likely account for these differences. The highest incidence of LF in Sierra Leone was observed during the dry season. LF cases were observed in ten of Sierra Leone's thirteen districts, with numerous cases from outside the traditional endemic zone. Deaths in patients presenting with LASV antigenemia were skewed towards individuals less than 29 years of age. Women self-reporting as pregnant were significantly overrepresented among LASV antigenemic patients. The CFR of ribavirin-treated patients presenting early in acute infection was lower than in untreated subjects. Conclusions/Significance: Lassa fever remains a major public health threat in Sierra Leone. Outreach activities should expand because LF may be more widespread in Sierra Leone than previously recognized. Enhanced case finding to ensure rapid diagnosis and treatment is imperative to reduce mortality. Even with ribavirin treatment, there was a high rate of fatalities underscoring the need to develop more effective and/or supplemental treatments for LF. Author Summary: Lassa fever (LF) is a major public health threat in West Africa. After the violent civil conflict in Sierra Leone (1991 to 2002) ended, the LF research program at Kenema Government Hospital (KGH) was reestablished. Higher CFRs in LF patients were observed compared to studies conducted prior to the civil conflict. The criteria used for defining the stages of LF and differences in sensitivity of the assays used likely account for these differences. LF may be more widespread in Sierra Leone than recognized previously. Peak presentation of LF cases occurs in the dry season, which is consistent with previous studies. Our studies also confirmed reports conducted prior to the civil conflict that indicate that infants, children, young adults, and pregnant women are disproportionately impacted by LF. High fatality rates were observed among both ribavirin treated and untreated patients, which underscores then need for better LF treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
26. Space-Time Trends in Lassa Fever in Sierra Leone by ELISA Serostatus, 2012–2019.
- Author
-
Shaffer, Jeffrey G., Schieffelin, John S., Momoh, Mambu, Goba, Augustine, Kanneh, Lansana, Alhasan, Foday, Gbakie, Michael, Engel, Emily J., Bond, Nell G., Hartnett, Jessica N., Nelson, Diana K. S., Bush, Duane J., Boisen, Matthew L., Heinrich, Megan L., Rowland, Megan M., Branco, Luis M., Samuels, Robert J., Garry, Robert F., Grant, Donald S., and Marzi, Andrea
- Subjects
LASSA fever ,SYMPTOMS ,ENZYME-linked immunosorbent assay ,HEMORRHAGIC diseases ,EBOLA virus disease - Abstract
Lassa fever (LF) is a viral hemorrhagic disease found in Sub-Saharan Africa and is responsible for up to 300,000 cases and 5000 deaths annually. LF is highly endemic in Sierra Leone, particularly in its Eastern Province. Kenema Government Hospital (KGH) maintains one of only a few LF isolation facilities in the world with year-round diagnostic testing. Here we focus on space-time trends for LF occurring in Sierra Leone between 2012 and 2019 to provide a current account of LF in the wake of the 2014–2016 Ebola epidemic. Data were analyzed for 3277 suspected LF cases and classified as acute, recent, and non-LF or prior LF exposure using enzyme-linked immunosorbent assays (ELISAs). Presentation rates for acute, recent, and non-LF or prior LF exposure were 6.0% (195/3277), 25.6% (838/3277), and 68.4% (2244/3277), respectively. Among 2051 non-LF or prior LF exposures, 33.2% (682/2051) tested positive for convalescent LF exposure. The overall LF case-fatality rate (CFR) was 78.5% (106/135). Both clinical presentations and confirmed LF cases declined following the Ebola epidemic. These declines coincided with an increased duration between illness onset and clinical presentation, perhaps suggesting more severe disease or presentation at later stages of illness. Acute LF cases and their corresponding CFRs peaked during the dry season (November to April). Subjects with recent (but not acute) LF exposure were more likely to present during the rainy season (May to October) than the dry season (p < 0.001). The findings here suggest that LF remains endemic in Sierra Leone and that caseloads are likely to resume at levels observed prior to the Ebola epidemic. The results provide insight on the current epidemiological profile of LF in Sierra Leone to facilitate LF vaccine studies and accentuate the need for LF cohort studies and continued advancements in LF diagnostics. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.